XML 46 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Revenue (Tables)
 12 Months Ended
Dec. 31, 2018
Revenue [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]
The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows:
($ in millions)
Balance at December 31, 2017
 
Adjustments Due to ASC 606
 
Balance at January 1, 2018
Assets:
 
 
 
 
 
Accounts receivable, net
$
253.2

 
$
25.0

 
$
278.2

Inventories
215.2

 
(20.8
)
 
194.4

Other current assets
39.2

 
(8.4
)
 
30.8

 
 
 
 
 
 
Liabilities and Equity:
 
 
 
 
 
Other current liabilities
$
77.0

 
$
(13.7
)
 
$
63.3

Deferred income taxes
10.4

 
3.0

 
13.4

Other long-term liabilities
42.6

 
(4.9
)
 
37.7

Retained earnings
1,178.2

 
11.4

 
1,189.6

The impact of the adoption of ASC 606 on our consolidated income statement for 2018 was as follows:
($ in millions)
As Reported
 
Balances without Adoption of ASC 606
 
Effects of Change (Lower)/Higher
Net sales
$
1,717.4

 
$
1,720.9

 
$
(3.5
)
Cost of goods and services sold
1,172.0

 
1,172.0

 
—

Other expense
1.9

 
1.2

 
0.7

Income tax expense
41.4

 
42.6

 
(1.2
)
Net income
$
206.9

 
$
209.9

 
$
(3.0
)
The impact of the adoption of ASC 606 on our consolidated balance sheet as of December 31, 2018 was as follows:
($ in millions)
As Reported
 
Balances without Adoption of ASC 606
 
Effects of Change Higher/(Lower)
Assets:
 
 
 
 
 
Accounts receivable, net
$
288.2

 
$
264.3

 
$
23.9

Inventories
214.5

 
234.4

 
(19.9
)
Other current assets
54.3

 
63.4

 
(9.1
)
 
 
 
 
 
 
Liabilities and Equity:
 
 
 
 
 
Other current liabilities
$
76.6

 
$
87.7

 
$
(11.1
)
Deferred income taxes
13.1

 
11.3

 
1.8

Other long-term liabilities
33.6

 
37.8

 
(4.2
)
Retained earnings
1,353.4

 
1,345.0

 
8.4
Disaggregation of Revenue [Table Text Block]
The following table presents the approximate percentage of our net sales by market group:
 
2018
 
2017 (1)
Biologics
21
%
 
23
%
Generics
21
%
 
20
%
Pharma
34
%
 
34
%
Contract-Manufactured Products
24
%
 
23
%
 
100
%
 
100
%
(1) As noted above, prior period amounts have not been adjusted under the modified retrospective method.
The following table presents the approximate percentage of our net sales by product category:
 
2018
 
2017 (1)
High-Value Components
41
%
 
41
%
Standard Packaging
32
%
 
32
%
Delivery Devices
3
%
 
4
%
Contract-Manufactured Products
24
%
 
23
%
 
100
%
 
100
%
(1) As noted above, prior period amounts have not been adjusted under the modified retrospective method.
The following table presents the approximate percentage of our net sales by geographic location:
 
2018
 
2017 (1)
Americas
48
%
 
51
%
Europe, Middle East, Africa
44
%
 
42
%
Asia Pacific
8
%
 
7
%
 
100
%
 
100
%
(1) As noted above, prior period amounts have not been adjusted under the modified retrospective method.
Contract with Customer, Asset and Liability [Table Text Block]
The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:
 
($ in millions)
Contract assets, December 31, 2017
$
7.5

Contract assets, December 31, 2018
9.1

Change in contract assets - increase (decrease)
$
1.6

 
 
Deferred income, December 31, 2017
$
(33.6
)
Deferred income, December 31, 2018
(33.4
)
Change in deferred income - decrease (increase)
$
0.2